DOCSLIB.ORG

Levitra Film Coated Tablet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

® LEVITRA 5 (La·vee·trah) ® LEVITRA 10 (La·vee·trah) ® LEVITRA 20 (La·vee·trah) vardenafil Consumer Medicine Information (CMI) WHAT IS IN THIS • nicorandil Levitra will only work if you are • sodium nitroprusside LEAFLET sexually aroused. It will not • isosorbide mononitrate This leaflet answers some increase your sex drive. • isosorbide dinitrate common questions about Levitra. • amyl nitrite (also known as It does not contain all the Levitra is not addictive. ‘poppers’, ‘amyl’ or ‘rush’) available information. It does not take the place of talking to your Ask your doctor if you have any Do not take Levitra if you are doctor or pharmacist. questions about why this taking: medicine has been prescribed • HIV protease inhibitors, All medicines have risks and for you. medicines used to treat HIV benefits. Your doctor has weighed Your doctor may have prescribed infection. Examples of HIV the risks of you taking Levitra it for another reason. protease inhibitors are against the benefits they expect it cobicistat, indinavir or will have for you. ritonavir. BEFORE YOU TAKE • Riociguat, used to treat a disease called pulmonary If you have any concerns about LEVITRA taking this medicine, ask your arterial hypertension. doctor or pharmacist. When you must not take it Because sexual activity may Do not take Levitra if you have place a strain on your heart, Keep this leaflet with the an allergy to: your doctor will need to check medicine. • any medicine containing whether you are fit enough to You may need to read it again. vardenafil hydrochloride have sexual intercourse. trihydrate • any of the ingredients listed at WHAT LEVITRA IS the end of this leaflet Do not take Levitra if you have: • unstable angina (chest pain) USED FOR • hypotension (low blood Some of the symptoms of an pressure) This medicine is used to treat allergic reaction may include: • uncontrolled hypertension (high erectile dysfunction. • shortness of breath blood pressure) • wheezing or difficulty • uncontrolled arrhythmia Erectile dysfunction, also known breathing (irregular heart beat) as impotence in adult males, is the • swelling of the face, lips, • ever had a condition involving inability to obtain and/or maintain tongue or other parts of the loss of vision due to damage to a hard erect penis sufficient for body the optic nerve from sexual activity. • rash, itching or hives on the insufficient blood supply skin known as non-arteritic anterior Levitra tablet contains the active optic neuropathy (NAION) ingredient vardenafil which works Do not take Levitra if you are • hereditary degenerative retinal by relaxing the blood vessels in the taking nitrate medicines which disorders (such as retinitis penis when you are sexually include: pigmentosa) aroused. This allows blood to flow • glyceryl trinitrate (also called • severe liver problems into the penis, allowing you to get nitroglycerine) an erection. Levitra 5 10 & 20 CMI 1 • severe kidney problems • sickle cell anaemia Dabigatran is an example for these requiring dialysis • bleeding disorders medicines. • been diagnosed with a disease • active stomach ulcer called pulmonary arterial • liver problems You may need to use different hypertension amounts of your medicine, or you If you have not told your doctor may need to take different Do not take Levitra if you have, or pharmacist about any of the medicines. Your doctor will be or have had, any of the following above, tell them before you start able to advise you. conditions within the previous 6 taking Levitra. months: Talk to your doctor if you are • myocardial infarction (heart Taking other medicines taking certain medicines for attack) arrhythmia, including quinidine, Tell your doctor or pharmacist if • stroke procainamide, amiodarone and you are taking any other • cardiac ischaemia sotalol. medicines, including those that • serious arrhythmia (irregular Levitra should not be used with heart beat) you buy without a prescription these medicines. from your pharmacy, Do not give Levitra to children, supermarket or health food Levitra tablets may be used adolescents or women. shop. together with an alpha-blocker if you are on stable alpha-blocker Some medicines may be affected Do not take this medicine after therapy. If your doctor by Levitra or vice versa. These the expiry date printed on the recommends this, they will start medicines include: pack or if the packaging is torn your Levitra treatment with a • nitrates, medicines for angina, or shows signs of tampering. lower dose. or nitric oxide donors, such as If it has expired or is damaged, amyl nitrite. Taking these return it to your pharmacist for Concomitant use of Levitra with medicines with Levitra could disposal. The EXPIRY date is alpha-blockers may contribute to seriously affect your blood marked on the strip of tablets as dizziness or fainting. pressure well as on the label of the carton. • For example, 11 18 refers to the cobicistat, ritonavir or Your doctor or pharmacist will eleventh month of 2018. indinavir, medicines for HIV also have a more complete list of • ketoconazole and itraconazole, medicines to be careful with or If you are not sure whether you used to treat fungal infections avoid while taking Levitra. should start taking this • erythromycin, clarithromycin medicine, talk to your doctor. and gatifloxacin, which are Ask your doctor or pharmacist, antibiotics if you are not sure if you are Before you start to take it • alpha-blockers, medicines used taking any of these medicines. to treat an enlarged prostate or Tell your doctor if you have high blood pressure. Examples allergies to any other medicines, of alpha-blockers are HOW TO TAKE foods, preservatives or dyes. terazosin, alfuzosin, tamsulosin and prazosin LEVITRA Tell your doctor if you have or • Riociguat, a type of medicine have had any of the following Follow all directions given to used to treat high blood you by your doctor or medical conditions: pressure in the arteries • any heart or blood vessel pharmacist carefully. carrying blood from your heart problems to your lungs • They may differ from the leukaemia (cancer of the blood • other treatments for erectile cells) information contained in this dysfunction leaflet. • multiple myeloma (a cancer of the bone marrow) Levitra might increase the amount Swallow the tablet whole with • any disease or deformity of of some medicines in your blood water. Levitra can be taken with your penis (sensitive P-gp substrates). or without food. • low or high blood pressure Levitra 5 10 & 20 CMI 2 If you do not understand the If you take too much instructions on the box, ask your (overdose) Please also be aware that you doctor or pharmacist for help. may have to take treatments like Immediately telephone your Levitra a few times before you doctor, or the Poisons get the best response. How much to take Information Centre (telephone If you’re still not getting a Your doctor or pharmacist will tell in Australia 13 11 26, in New response, speak to your doctor. you how much and how often you Zealand 0800 POISON or 0800 should take Levitra. Follow the 764 766), or go to the accident directions given to you by your and emergency department at Things you must not do doctor or pharmacist carefully. your nearest hospital, if you Do not use the recreational drug They may differ from the think you or anyone else may amyl nitrite (sometimes called information contained in this have taken too much Levitra. ‘poppers’, ‘amyl’ or ‘rush’) leaflet. Do this even if there are no signs while you are taking Levitra. of discomfort or poisoning. The dose ranges from 5 mg to Do not take Levitra if you are 20 mg. Your doctor will You may need urgent medical taking HIV protease inhibitors, determine the correct dose for you attention. medicines used to treat HIV depending on your condition, infection. other medicines and response. Do not take more than one dose WHILE YOU ARE Do not take Levitra if you are of Levitra a day. taking Riociguat, used to treat USING LEVITRA pulmonary arterial When to take it Things you must do hypertension. Sexual stimulation is required Tell all the doctors, dentists and for a natural response to If you get an angina attack pharmacists who are treating treatment with Levitra. whilst taking Levitra, do not you that you are taking Levitra. take nitrate medicines to relieve Take your dose of Levitra 25 to If you are about to start taking the pain. Tell your doctor 60 minutes before you wish to any new medicines, especially immediately or contact your have sex. nitrates or some medicines to nearest emergency department. treat HIV, e.g. cobicistat, Make sure that your doctor knows Levitra may work as soon as 15 indinavir or ritonavir, tell your you are taking Levitra tablets. minutes and as long as 4-5 hours doctor or pharmacist that you after taking it. The amount of time are taking Levitra. Do not take more than one dose it takes to start working varies of Levitra a day. If Levitra does from person to person. Stop taking Levitra and tell your not help you get an erection, or if doctor if you notice a sudden your erection does not last long If you are also taking an alpha- decrease or loss of hearing. enough to complete sexual blocker other than tamsulosin or Ringing of the ears and dizziness intercourse, tell your doctor. alfuzosin, allow at least 6 hours may also occur. between the time you take it and Do not give your Levitra tablets the time you take your Levitra Stop taking Levitra and tell your to anyone else, even if they have tablet (see Taking other doctor if you notice a sudden loss the same condition as you. medicines). Tamsulosin can be in vision.
Recommended publications
  • Pneumocystis Pneumonia and Disseminated

    Pneumocystis Pneumonia and Disseminated

    1614 BRITISH MEDICAL JOURNAL VOLUmE 286 21 MAY 1983 Br Med J (Clin Res Ed): first published as 10.1136/bmj.286.6378.1614-a on 21 May 1983. Downloaded from Pneumocystis pneumonia and discussions, and Dr B Jameson and Dr D G Fleck for their valuable assistance disseminated toxoplasmosis in a with the pneumocystis and toxoplasma serology. Ammann A, Cowan M, Wara D, et al. Possible transfusion-associated male homosexual acquired immune deficiency syndrome (AIDS)-California. Morbidity and Mortality Weekly Report 1982;31 :652-4. 2 Du Bois RM, Branthwaite MA, Mikhail JR, et al. Primary pneumocystis Within the past two years 788 cases of the apparently new and carinii and cytomegalovirus infections. Lancet 1981 ;ii: 1339. potentially lethal syndrome of acquired immune deficiency have been Oswald GA, Theodossi A, Gazzard BG, et al. Attempted immune stimula- reported in the United States.' Only three cases have been reported in tion in the "gay compromise syndrome." Br MedJ' 1982;285:1082. the United Kingdom.2-4 We report a case in a previously healthy 37 4 Maurice PDL, Smith NP, Pinching AJ. Kaposi's sarcoma with benign course in a homosexual. Lancet 1982;i:571. year old male homosexual who was initially diagnosed and treated for Task force on acquired immune deficiency syndrome, Centers for Disease pneumocystis pneumonia and subsequently died of widespread Control. Update on acquired immune deficiency syndrome (AIDS)- toxoplasmosis. United States. Morbidity and Mortality Weekly Report 1982;31:507-14. (Accepted 4 March 1983) Case report The patient presented with an eight week history of malaise, non-produc- Departments of Microbiology and Medicine, St Thomas's Hospital, tive cough, night sweats, diarrhoea, anorexia, and weight loss.
  • ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity

    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity

    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity Agency for Toxic Substances and Disease Registry Case Studies in Environmental Medicine (CSEM) Nitrate/Nitrite Toxicity Course: WB2342 CE Original Date: December 5, 2013 CE Expiration Date: December 5, 2015 Key • Nitrate toxicity is a preventable cause of Concepts methemoglobinemia. • Infants younger than 4 months of age are at particular risk of nitrate toxicity from contaminated well water. • The widespread use of nitrate fertilizers increases the risk of well-water contamination in rural areas. About This This educational case study document is one in a series of and Other self-instructional modules designed to increase the primary Case Studies care provider’s knowledge of hazardous substances in the in environment and to promote the adoption of medical Environmen- practices that aid in the evaluation and care of potentially tal Medicine exposed patients. The complete series of Case Studies in Environmental Medicine is located on the ATSDR Web site at URL: http://www.atsdr.cdc.gov/csem/csem.html In addition, the downloadable PDF version of this educational series and other environmental medicine materials provides content in an electronic, printable format. Acknowledgements We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Contributors to this version of the Case Study in Environmental Medicine are listed below. Please Note: Each content expert for this case study has indicated that there is no conflict of interest that would bias the case study content. CDC/ATSDR Author(s): Kim Gehle MD, MPH CDC/ATSDR Planners: Charlton Coles, Ph.D.; Kimberly Gehle, MD; Sharon L.
  • Nitrocompounds, Aliphatic: Physical & Chemical Properties

    Nitrocompounds, Aliphatic: Physical & Chemical Properties

    Nitrocompounds, Aliphatic: Physical & Chemical Properties, Encyclopaedia of Occupational Health and Safety, Jeanne Mager Stellman, Editor-in-Chief. International Labor Organization, Geneva. 2011 Chemical Name Colour/Form Boiling Point Melting Molecular Solubility in Relative Density Relative Vapour Inflam. Flash Auto CAS-Number (°C) Point (°C) Weight Water (water=1) Vapour Pressure/ Limits Point (ºC) Ignition Density (Kpa) Point (º C) (air=1) AMYL NITRITE yellowish, transparent 99 117.1 sl sol 0.8828 4.0 110-46-3 liquid 1-CHLORO-1-NITRO- 124.5 109.51 insol 1.2837 ETHANE 598-92-5 2-CHLORO-2-NITRO- liquid 133.6 123.55 0.5 ml sol in 1.197 4.3 8.5 mm Hg 57 ° C oc PROPANE 100 ml @ 20 ° C/20 ° @ 25 ° C 594-71-8 @ 20 ° C C 1-CHLORO-1-NITRO- liquid 143 123.54 0.5ml/100 ml 1.209 0.3 5.8 mm Hg 62 oc PROPANE @ 25 ºC 600-25-9 CHLOROPICRIN slightly oily liquid; 112 -69.2 164.4 sol 1.6558 5.7 5.7 mm Hg 76-06-2 colourless; faint yellow @ 0 º C liquid. 1,1-DICHLORO-1-NI- colourless liquid 124 143.9 0.25 ml/100 m 1.4271 5.0 16.0 mm Hg 76 oc TROETHANE l @ 25 ºC 594-72-9 DIETHYLENE GLYCOL liquid 161 -11.6 sl sol 1.377 DINITRATE @ 25 ºC 693-21-0 ETHYLENE GLYCOL yellowish, oily liquid; 197-200 -22.3 152.06 insol 1.4918 5.24 7 Pa 215 cc 114 DINITRATE colourless 628-96-6 ETHYLENE GLYCOL pale yellow, viscous liquid 197-200 -22.3 152.06 sl sol 1.4978 218 DINITRATE mixed with NITROGLYCERIN (1:1) 53569-64-5 ETHYL NITRATE colourless liquid 87.2 ° C at 762 94.6 ° C 91.07 1.3 g in 100 1.1084 at 20 ° 3.1 lower, 4.0% 10 625-58-1 mm Hg ml C/4 ° C by vol @ 55 ° C ETHYL
  • The History of Glyceryl Trinitrate As a Prescription Drug

    The History of Glyceryl Trinitrate As a Prescription Drug

    patches for transdermal delivery and in tablet form. It ARTICLE may also be injected. Th e history of glyceryl trinitrate as a prescription drug Anthony Butler Abstract A number of prescribed drugs possessing a nitro group (-NO2) are vasodilators and are used to relieve the symptoms of angina pectoris. Th e most widely pre- scribed drug in this group is glyceryl trinitrate (GTN). It was fi rst synthesized by an Italian chemist, Ascanio Sobrero, in 1847. Its clinical use was pioneered by phy- sicians including William Murrell and Sir Th omas Lauder Brunton, and it is now an established remedy for the condition. Its mode of action in vivo was a com- plete mystery until the discovery in the 1980s of nitric oxide (NO) as the naturally occurring messenger mol- ecule that triggers the process of vasodilation. However, exactly how the nitro group in GTN is converted into NO is still uncertain, although the general belief is that an enzyme is responsible. Introduction Th e nineteenth and twentieth centuries witnessed a Figure 1. Ascanio Sobrero. (Source: University of Torino surge in the number of new compounds made in the Archive) laboratory that were available for testing as possible drugs. Not only were the physical properties (colour, GTN was fi rst synthesised by an Italian, Ascanio So- crystal form, melting point and so on) of new com- brero (1812-1888) around 1847. (Figure 1). He was born pounds recorded, but the discoverer might do a few in the small town of Casale Monferrato in the Pied- simple tests to see whether the compound had any in- mont region of Italy and studied medicine at the near- teresting biological properties.
  • NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE Criteria for a Recommended Standard OCCUPATIONAL EXPOSURE to NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE

    NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE Criteria for a Recommended Standard OCCUPATIONAL EXPOSURE to NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE

    CRITERIA FOR A RECOMMENDED STANDARD OCCUPATIONAL EXPOSURE TO NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE criteria for a recommended standard OCCUPATIONAL EXPOSURE TO NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Center for Disease Control National Institute for Occupational Safety and Health June 1978 For »ale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402 DISCLAIMER Mention of company name or products does not constitute endorsement by the National Institute for Occupational Safety and Health. DHEW (NIOSH) Publication No. 78-167 PREFACE The Occupational Safety and Health Act of 1970 emphasizes the need for standards to protect the health and provide for the safety of workers occupationally exposed to an ever-increasing number of potential hazards. The National Institute for Occupational Safety and Health (NIOSH) evaluates all available research data and criteria and recommends standards for occupational exposure. The Secretary of Labor will weigh these recommendations along with other considerations, such as feasibility and means of implementation, in promulgating regulatory standards. NIOSH will periodically review the recommended standards to ensure continuing protection of workers and will make successive reports as new research and epidemiologic studies are completed and as sampling and analytical methods are developed. The contributions to this document on nitroglycerin (NG) and ethylene glycol dinitrate (EGDN) by NIOSH staff, other Federal agencies or departments, the review consultants, the reviewers selected by the American Industrial Hygiene Association, and by Robert B. O ’Connor, M.D., NIOSH consultant in occupational medicine, are gratefully acknowledged. The views and conclusions expressed in this document, together with the recommendations for a standard, are those of NIOSH.
  • US5489610.Pdf

    US5489610.Pdf

    |||||||| US00548961OA United States Patent 19 11 Patent Number: 5,489,610 Fung et al. 45) Date of Patent: 8 Feb. 6, 1996 54 SUSTAINED RELEASE ORGANIC NITRITE 58 Field of Search .................................... 514/506, 509, THERAPY 514/645, 740 75 Inventors: Ho-Leung Fung, Getzville; John A. 56) References Cited Bauer, Williamsville, both of N.Y. U.S. PATENT DOCUMENTS 73 Assignee: Research Foundation of the State 5,278,192 l/1994 Fung et al. .............................. 514f645 University of New York, Albany, N.Y. OTHER PUBLICATIONS * Notice: The portion of the term of this patent Derwent Abstracts 78–35053A, "Medicaments for Treating disclaimed.subsequent to Jan. 11, 2011, has been Cardiardiogenic Shock”, Fribolinis is et al. (1978). Patent Abstracts of Japan, vol. 12, No. 467, Dec. 7, 1988, 21 Appl. No.: 199,280 "Tape Preparation'. 22, PCT Filed: Jun. 30, 1993 Primary Examiner-Frederick Krass Attorney, Agent, or Firm-Kirschstein et al. 86 PCT No.: PCT/US93/06235 (57) ABSTRACT S371 Date: Mar. 1, 1994 A method of treating a patient suffering from a condition S 102(e) Date: Mar. 1, 1994 requiring vasodilator therapy, comprising long term, con 87 PCT Pub. No.: WO94/01103 tinuous adminstration of an organic nitrite to the patient in a dosage form capable of delivering a sufficient therapeutic PCT Pub. Date:Jan. 20, 1994 amount of nitrite to the bloodstream of the patient thereby providing effective vasodilator therapy for at least 24 hours Related U.S. Application Data without the development of tolerance in the patient. The a method of the invention is useful in treating conditions such 63 Continuation-in-part of Ser.
  • Cocaine/Heroin Induced Rhabdomyolysis and Ventricular Fibrillation B Mccann, R Hunter, J Mccann

    Cocaine/Heroin Induced Rhabdomyolysis and Ventricular Fibrillation B Mccann, R Hunter, J Mccann

    264 CASE REPORTS Emerg Med J: first published as 10.1136/emj.19.3.270 on 1 May 2002. Downloaded from Cocaine/heroin induced rhabdomyolysis and ventricular fibrillation B McCann, R Hunter, J McCann ............................................................................................................................. Emerg Med J 2002;19:264–265 PaO2: 24.3 kPa; base deficit: 18.0 mmol/l; lactate: 8.4 mmol/l. A case of cardiorespiratory arrest in a 28 year old Creatine phosphokinase: 90 500 IU/l (normal range 33–194). man after cocaine and heroin ingestion is described. The Urine: myoglobin: positive; cocaine metabolites: positive; arrest is attributed primarily to hyperkalaemia/ opioids: positive. rhabdomyolysis—a recognised consequence of each of Consequent upon his rhabdomyolysis he developed acute these drugs. The administration of naloxone may have renal failure requiring haemodialysis, disseminated intravas- been contributory. He developed acute renal failure, cular coagulopathy and right lower limb compartment disseminated intravascular coagulopathy with consequent syndrome requiring fasciotomy. Echocardiogram showed a lower limb compartment syndrome requiring fasciotomy. left ventricular ejection fraction of 53%. Respiratory function Ventricular fibrillation was identified at thoracotomy. remained stable. At day 10 (after tracheostomy) he had spon- taneous eye opening, flexed to pain and had no response to verbal commands. Brain stem reflexes were intact. Computed tomographic scan of his brain was normal. 28 year old man was brought to the emergency depart- The patient died two months later. Cause of death was ment after intravenous ingestion of cocaine and heroin. bronchopneumonia complicating multiorgan failure. AHe was noted to be pale, cyanosed, bradypnoeic (6/min), and hypotensive (70/40). DISCUSSION Initial treatment consisted of oxygen via a facemask, and 800 Rhabdomyolysis is a well documented complication of cocaine µg of naloxone intravenously.
  • Hazard Summary Identification Reason For

    Hazard Summary Identification Reason For

    Common Name: AMYL NITRITE CAS Number: 110-46-3 RTK Substance number: 0132 DOT Number: UN 1113 Date: March 1987 Revised: September 2000 ----------------------------------------------------------------------- ----------------------------------------------------------------------- HAZARD SUMMARY * Amyl Nitrite can affect you when breathed in and by * Exposure to hazardous substances should be routinely passing through your skin. evaluated. This may include collecting personal and area * Contact can irritate the skin and eyes and may cause air samples. You can obtain copies of sampling results blurred vision. from your employer. You have a legal right to this * Breathing Amyl Nitrite can irritate the nose and throat information under OSHA 1910.1020. causing coughing and wheezing. * If you think you are experiencing any work-related health * Exposure to Amyl Nitrite can cause nausea, vomiting, problems, see a doctor trained to recognize occupational weakness, confusion, restlessness and convulsions. diseases. Take this Fact Sheet with you. * High levels can interfere with the ability of the blood to carry Oxygen causing headache, fatigue, dizziness, and a WORKPLACE EXPOSURE LIMITS blue color to the skin and lips (methemoglobinemia). No occupational exposure limits have been established for Higher levels can cause trouble breathing, collapse and Amyl Nitrite. This does not mean that this substance is not even death. harmful. Safe work practices should always be followed. * Repeated exposure may damage the blood cells causing a low blood count (anemia). * It should be recognized that Amyl Nitrite can be absorbed * Amyl Nitrite is a HIGHLY FLAMMABLE and through your skin, thereby increasing your exposure. REACTIVE chemical and a DANGEROUS FIRE and EXPLOSION HAZARD. WAYS OF REDUCING EXPOSURE * Where possible, enclose operations and use local exhaust IDENTIFICATION ventilation at the site of chemical release.
  • Hazardous Waste List (California Code of Regulations, Title 22 Section 66261.126)

    Hazardous Waste List (California Code of Regulations, Title 22 Section 66261.126)

    Hazardous Waste List (California Code of Regulations, Title 22 Section 66261.126) Appendix X - List of Chemical Names and Common Names for Hazardous Wastes and Hazardous Materials (a) This subdivision sets forth a list of chemicals which create a presumption that a waste is a hazardous waste. If a waste consists of or contains a chemical listed in this subdivision, the waste is presumed to be a hazardous waste Environmental Regulations of CALIFORNIA unless it is determined that the waste is not a hazardous waste pursuant to the procedures set forth in section 66262.11. The hazardous characteristics which serve as a basis for listing the chemicals are indicated in the list as follows: (X) toxic (C) corrosive (I) ignitable (R) reactive * =Extremely Hazardous A chemical denoted with an asterisk is presumed to be an extremely hazardous waste unless it does not exhibit any of the criteria set forth in section 66261.110 and section 66261.113. Trademark chemical names are indicated by all capital letters. 1. Acetaldehyde (X,I) 2. Acetic acid (X,C,I) 3. Acetone, Propanone (I) 4. *Acetone cyanohydrin (X) 5. Acetonitrile (X,I) 6. *2-Acetylaminofluorene, 2-AAF (X) 7. Acetyl benzoyl peroxide (X,I,R) 8. *Acetyl chloride (X,C,R) 9. Acetyl peroxide (X,I,R) 10. Acridine (X) 11. *Acrolein, Aqualin (X,I) 12. *Acrylonitrile (X,I) 13. *Adiponitrile (X) 14. *Aldrin; 1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4,5,8-endo-exodimethanonaphthlene (X) 15. *Alkyl aluminum chloride (C,I,R) 16. *Alkyl aluminum compounds (C,I,R) 17.
  • Amyl Nitrate Is Also Referred to As

    Amyl Nitrate Is Also Referred to As

    Amyl Nitrate Is Also Referred To As Vitreum Jared browsed her hoovers so downright that Shane disguisings very astringently. Treeless soand septennially ascitic Christof or misteach always recreate any unrestraints much and meteorologically. hogties his ranches. Exarate Micheal never overpeopled Initial epidemiologic studies indicated that gentle use of inhalant drugs such as amyl nitrite isobutyl nitrite IBN and butyl nitrite may raise a risk factor for acquired. Using amyl nitrate from. Users often also referred to amyl nitrite. What are Poppers Where they even Be Purchased and Dangers. Can nitrates be added to a sign schedule or allow scripting from sexual health practitioners? Clinical and nitrates. Using too much amyl nitrite may prefer a dangerous overdose If regular medicine does science seem fine be plenty as old after money have used it require a while check been your doctor to not pocket the dose on my own. The patient was maintained in the method is common are swallowed, that pushed underground into the fumes for example, dizziness and severity of aids in. Alkyl nitrates also refers to amyl is our patient had thrombocytopenia, with reference entry into phosgene and levels can potentially deadly substance choice for. Amyl nitrite Rx Medscape Reference. Burroughs wellcome and to as literature, but notthat of the manufacturing nitroglycerin or vitals and sometimes serious lung metabolism. Nitrite are two very similar to psychological withdrawal is not result in these products to dilate the rat by particular sections of subjects. The nitrate is to nitrates are referred to browse this? Diseases and contaminants: nitrate and drinking water or private wells.
  • Health Hazards of Nitrite Inhalants, 83

    Health Hazards of Nitrite Inhalants, 83

    Health Hazards of Nitrite Inhalants U.S. DEPARMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Health Hazards of Nitrite Inhalants Editors: Harry W. Haverkos, M.D. Divlsion of Clinical Research National Institute on Drug Abuse John A. Dougherty, Ph.D. Veterans Administration Medical Center Lexington, KY NIDA Research Monograph 83 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5500 Fishers Lane Rockville, MD 20857 For Sale by the Superitendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple Universlty School of Medicine National Federation of Parents for Philadelphia, Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic Institute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C GILBERT J.
  • THE DIAGNOSIS and TREATMENT of CARDIAC PAIN. by Amyl Nitrite

    THE DIAGNOSIS and TREATMENT of CARDIAC PAIN. by Amyl Nitrite

    April, 1936 DIAGNOSIS AND TREATMENT OF CARDIAC PAIN 129 Postgrad Med J: first published as 10.1136/pgmj.12.126.129 on 1 April 1936. Downloaded from THE DIAGNOSIS AND TREATMENT OF CARDIAC PAIN. By GEOFFREY BOURNE, M.D., F.R.C.P. (Assistant Physician, Officer in charge Cardiology Dept., St. Bartholomew's Hospital; Physician, King George Hospital, Ilford.) The most necessary factor in treatment is accurate diagnosis and there is no subject where this is more true than in that of cardiac pain. The chief con- ditions in which cardiac pain occurs are, I. Coronary Thrombosis, 2. Angina of Effort, 3. Spasmodic Angina, and 4. Angina Innocens. I. CORONARY THROMBOSIS. Coronary thrombosis is now well recognized as a clinical entity, and its symptoms and signs are understandable in the light of the pathological changes Protected by copyright. which are found by post-mortem examination. Pathology and Symptoms. The sudden blocking of the artery produces an abrupt anaemia of a consider- able mass of living heart muscle. This produces pain. Certain changes take place in the infarcted area, necrosis, fibrosis, and to a certain extent recovery which occurs by virtue of the presence of some collateral circulation at the periphery of the infarct. As these changes proceed, the pain slowly dies down, and has generally completely disappeared by the end of the week. The amount of pain varies greatly from case to case, and in some cases is comparatively mild. The characteristics of the process are the sudden onset, the fact that the pain http://pmj.bmj.com/ is at its greatest at first, and that it slowly subsides during a period of days.